NaNO-DENGUE_ddi
RACINE, Céline
2023-12-13
Nesstar Publisher
A Phase I, double-blind, randomized, vehicle-controlled, dose-finding, safety study of a synthetic nanoparticle-based, T cell priming peptide vaccine against Dengue virus in healthy adults in Switzerland
naNO-DENGUE: Étude de phase I randomisée, contrôlée par nano-vecteur, en double-aveugle, 19 évaluant la sécurité d’emploi et la dose adéquate d’un vaccin synthétique peptidique contre le virus de la dengue à base de nanoparticules induisant les lymphocytes T, chez des adultes en bonne santé en Suisse
10.16909-DATASET-43
GENTON, Blaise
HARTLEY, Mary-Anne
BESSON, Juliette
MABY EL HAJJAMI, Hélène
KARLEN, Maxime
WARPELIN DECRAUSAZ, Loane
SENE, Loredana
SCHAUFELBERGER, Sylvain
FAIVRE, Vincent
MIAUTON, Alix
FAOUZI, Mohamed
SPERTINI, François
AUDRAN, Régine
Nesstar Publisher
Emergex Vaccines Holding Limited
Dengue vaccine
Dengue virus
T cell immunity
Nanoparticle-based vaccine
Switzerland
Switzerland
Individuals. 26 participants were enrolled.
Clinical data and laboratory data (safety)
RACINE, Céline (repository manager)
GENTON, Blaise
MIAUTON A, AUDRAN R, BESSON J, MABY-EL HAJJAMI H, KARLEN M, WARPELIN-DECRAUSAZ L, SENE L, SCHAUFELBERGER S, FAIVRE V, FAOUZI M, HARTLEY MA, SPERTINI F, GENTON B. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland. Version 1.0 of the data dictionary, provided by the Unisanté Research Data Repository. DOI:10.16909/DATASET/43
The dataset can't be share due to ethical restriction. Only the codebook is made available.